Findings based on review of national versus WHO guidelines
COVID-19
The CDC Advisory Committee on Immunization Practices February meeting covered vaccinations for COVID-19, influenza, RSV, and pneumococcal infections.
Time to sustained alleviation of COVID-19 symptoms not significantly shorter with nirmatrelvir-ritonavir versus placebo
Second booster dose resulted in 123,869 fewer hospitalizations and 5,524 fewer deaths versus single-dose campaign.
Increase seen during pandemic period, following decrease between 1950 and 2019; child mortality continued to drop during pandemic.
The rate of routine vaccination in the US has dropped below the 95% needed to provide protection for the general population. Here are some tips to help reduce anxiety around vaccinations.
The phase 3 NextCOVE study compared the safety, reactogenicity, relative vaccine efficacy and immunogenicity of mRNA-1283 to Moderna’s licensed COVID-19 vaccine, Spikevax.
Pemgarda is a SARS-CoV-2 spike protein-directed attachment inhibitor.
Authors say findings show role for microbiome and development of long COVID symptoms.
Postinfection incident neurologic diagnoses observed in 2.79 and 4.91% of COVID-19 and influenza cohorts, respectively.
- Loading...
